Asset Details
Do you wish to reserve the book?
Myasthenia gravis: the future is here
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Myasthenia gravis: the future is here
Do you wish to request the book?
Myasthenia gravis: the future is here
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Myasthenia gravis: the future is here
2024
Overview
Myasthenia gravis (MG) stands as a prototypical antibody-mediated autoimmune disease: it is dependent on T cells and characterized by the presence of autoantibodies targeting proteins located on the postsynaptic surface of skeletal muscle, known as the neuromuscular junction. Patients with MG exhibit a spectrum of weakness, ranging from limited ocular muscle involvement to life-threatening respiratory failure. Recent decades have witnessed substantial progress in understanding the underlying pathophysiology, leading to the delineation of distinct subcategories within MG, including MG linked to AChR or MuSK antibodies as well as age-based distinction, thymoma-associated, and immune checkpoint inhibitor-induced MG. This heightened understanding has paved the way for the development of more precise and targeted therapeutic interventions. Notably, the FDA has recently approved therapeutic inhibitors of complement and the IgG receptor FcRn, a testament to our improved comprehension of autoantibody effector mechanisms in MG. In this Review, we delve into the various subgroups of MG, stratified by age, autoantibody type, and histology of the thymus with neoplasms. Furthermore, we explore both current and potential emerging therapeutic strategies, shedding light on the evolving landscape of MG treatment.
Publisher
American Society for Clinical Investigation
Subject
/ Antigens
/ B cells
/ Disease
/ Fatigue
/ Histocompatibility Antigens Class I - immunology
/ Humans
/ Immune checkpoint inhibitors
/ Kinases
/ Muscles
/ Myasthenia Gravis - immunology
/ Myasthenia Gravis - pathology
/ Patients
/ Proteins
/ Receptor Protein-Tyrosine Kinases - antagonists & inhibitors
/ Receptor Protein-Tyrosine Kinases - immunology
/ Receptors, Cholinergic - immunology
/ Review
/ T cells
/ Thymoma
